Schedule 13G ownership disclosure
Y-MABS THERAPEUTICS INC
Common Stock · CUSIP: 984241109
Event date: 2025-08-05
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Beryl Capital Management LLC
Shares: 4,087,091.00 · Class: 9.0%
- Beryl Capital Management LP
Shares: 4,087,091.00 · Class: 9.0%
- Beryl Capital Partners II LP
Shares: 3,095,833.00 · Class: 6.8%
- David A. Witkin
Shares: 4,087,091.00 · Class: 9.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000935836-25-000492
- Form type
- SCHEDULE 13G
- Filer
- Beryl Capital Management LLC
- CIK
- CIK 1719307
- Filed
- Aug 12, 2025
- Reporting period
- Aug 05, 2025
- Description
- Schedule 13G beneficial ownership